Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2114057 | Cancer Letters | 2010 | 8 Pages |
Abstract
VEGF receptor blockage has been reported to increase serum VEGF. We hypothesized that mTOR inhibition by everolimus counteracts VEGF induction by sunitinib resulting in an improved anti-tumor activity of sunitinib. In vitro, sunitinib in combination with everolimus did not outperform the respective monotherapies. In vivo, monotherapies reduced tumor growth by 60%, whereas the combination of sunitinib and everolimus led to an almost complete tumor growth inhibition. This superior anti-tumor activity coincided with attenuation of VEGF peaks. In conclusion mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and results in significant reduction of tumor burden and long-lasting tumor growth control.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Thorsten Fuereder, Agnes Jaeger-Lansky, Doris Hoeflmayer, Matthias Preusser, Sabine Strommer, Daniel Cejka, Stefan Koehrer, Richard Crevenna, Volker Wacheck,